Quantcast

Latest Insulin analog Stories

2014-09-18 08:29:16

Denmark's Crown Prince Couple Help Celebrate Canadian, Danish Partnership, Marking Novo Nordisk's 30 Years in Canada MISSISSAUGA, ON, Sept. 18, 2014 /CNW/ - Danish-based pharmaceutical company Novo Nordisk, in collaboration with the Royal Danish Consulate General and the Canadian Diabetes Association (CDA), is hosting "Innovation in Diabetes Care: 90 Years and Beyond" at the MaRS Discovery District today, to highlight the significant contribution Canada has made to diabetes care, and...

2014-09-16 08:29:41

Clinical Trials Mark Important Milestone in Development of Two Highly Complex Products PITTSBURGH, Sept. 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, today announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's Advair Diskus® and its insulin analog to Sanofi's Lantus®. http://photos.prnewswire.com/prnvar/20140423/77793 In October 2014, Mylan will commence a Phase III...

2014-07-25 12:24:51

ALBANY, New York, July 25, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and Human Insulin) - Industry Analysis, Size, Share, Growth, Trends and Forecast (Value and Volume), 2013 - 2019", the global insulin market was valued at USD 19.99 billion in 2012 and is expected to grow at a CAGR of 6.1% from 2013 to 2019 to...

2014-06-14 12:21:03

-- Real World Outcome Study of Patients with Type 2 Diabetes Presented at American Diabetes Association 74th Scientific Sessions -- BRIDGEWATER, N.J., June 14, 2014 /PRNewswire/ -- Sanofi US announced today results from a real world outcome study of type 2 diabetes (T2D) patients that show switching from Lantus® (insulin glargine [rDNA origin] injection) to insulin detemir demonstrated higher average blood sugar levels (A1C) and lower A1C reduction over a span of 12 months compared...

2014-06-14 12:20:43

Data presented at the 74th American Diabetes Association Scientific Sessions® expand body of evidence for the mechanism of action of basal insulin peglispro in healthy human subjects SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data regarding the mechanism of action of basal insulin peglispro (BIL). When BIL and insulin glargine were each administered to achieve complete suppression of glucose production, which principally comes from the...

2014-04-03 12:30:42

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global and China Insulin Industry Report, 2013-2017 As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%. And insulin as the important diabetes medication has also seen increasing...

2014-03-24 23:24:35

MarketOptimizer.org offers “PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store. Dallas, Texas (PRWEB) March 24, 2014 This report focuses on type 2 diabetes pharmaceuticals in seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) and three emerging markets (China, India and Brazil). These 10 markets will be referred to as the global market. The global type 2 diabetes pharmaceutical markets in the 2012...

2014-03-25 00:23:22

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/kz2b9w/investigation) has announced the addition of the "Investigation Report on China Insulin Glargine Market, 2009-2018" [http://www.researchandmarkets.com/research/kz2b9w/investigation ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) With the improvement of people's living standard and changing of...

2014-03-10 23:04:30

ChinaMarketResearchReports.com adds Latest Reports on China Insulin Aspart & Lispro Market to its store. Dallas, TX (PRWEB) March 10, 2014 According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with more than 380 million patients worldwide. On December 26, 2001 Novo Nordisk announced that the first insulin analogue insulin aspart (marketed by Novo Nordisk with the trade name "Novorapid") to treat...

2014-02-28 23:01:12

ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Insulin Glargine Market, 2009-2018” to its store. Dallas, TX (PRWEB) March 01, 2014 Description With the improvement of people's living standard and changing of lifestyles, as well as deepening of the aging of society, prevalence rate of diabetes keeps rising, making it the third most threatening chronic disease to human health after tumor and cardiovascular disease. Its risk to disable or kill has...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related